The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
Open accessAbstract
BACKGROUND: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission. METHODS: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (41%) [corrected] used only ChEIs, and 416 (44.1%) [corrected] used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications). RESULTS: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death. CONCLUSIONS: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Short-term (6-12 months) RCTs (level I evidence), longer-term (12-36 months) openlabel extensions of RCTs (level II or III evidence), and long-term (2 to 5-plus years) observational prospective clinical cohort effectiveness studies (level II evidence) support the safety and benefits of anti-AD treatments in combination, most frequently as memantine added on to a stable regimen of background ChEI”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [117]
In the citing paper
“Longer-term prospective observational clinical patient cohort studies report reduced clinical decline in patients with AD treated at any stage.[114][115][116][117][118][119]”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167
Research works printed but not linked: 1
- [32]APA Diagnostic and statistical manual on mental disorders—Revised (DSM-III-R) 1987 3rd edn. Washington, DC American Psychiatric Press
Cited by
Sorted by citations
Items 201–267 of 267
The use of acetyl cholinesterase inhibitors and memantine in nursing home residents.
Gorus, E., Puyvelde, K. V., Corremans, V., & Mets, T. F. (2011) · PubMed · doi:10.2143/acb.66.5.2062587 · Cited by 1
Management of Alzheimer’s Disease Using disease-modifying Drugs
Gauthier, S. G. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.37 · Cited by 1
Barriers to evidence-based prescribing in Alzheimer's disease
Ballard, C. G. (2013) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2013.2.1.16 · Cited by 2
Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia.
Parsons, C., Hughes, C. M., McGuinness, B., & Passmore, P. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009081 · Cited by 1
Tifratène, K., Duff, F. L., Pradier, C., Quetel, J., Lafay, P., Schück, S., Benzenine, É., Quantin, C., & Robert, P. H. (2012) · Cited by 1
Prediction of general hospital admission in people with dementia
Parra, M. A., Lim, A. E., Connelly, P., & Starr, J. M. (2016) · Cited by 1
Promoting the Behavioral Health of Persons with Neurocognitive Disorders
Singer, J., Chong, A. K., Hisaka, R., & Fisher, J. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-93003-9_16 · Cited by 1
Dementia of the Alzheimer type: current state of the problem
Tyuvina, N. A., & Владимировна, Б. В. (2014) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2014-1-61-67 · Cited by 1
Larner, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-75259-4_10 · Cited by 1
Potocnik, F. C. V. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.944 · Cited by 1
Barriers to evidence-based prescribing in Alzheimer's disease
Ballard, C. G. (2013) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2013.2.1.97534 · Cited by 1
Capabilities of combined therapy of Alzheimer’s disease
Васенина, Е. Е., Veryugina, N. I., & Levin, O. S. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212211245 · Cited by 1
Zhao, G., Zhao, S., & Xie, X. (2023) · Springer eBooks · doi:10.1007/978-981-99-1284-1_32 · Cited by 1
Pharmacological Approaches and Herbal Interventions for Alzheimer's Disease
Kumar, S., Singh, S., Rajput, D., Sharma, B., Chaturvedi, K., Singh, N., Saha, S., Singh, K., & Mukherjee, S. (2024) · The Natural Products Journal · doi:10.2174/0122103155275266231123090138 · Cited by 13
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.2 · Cited by 1
Sobów, T. (2014) · Aktualności Neurologiczne · doi:10.15557/an.2014.0006 · Cited by 1
[New perspectives on Alzheimer's disease from neuroimaging].
Becker, J. T. (2010) · PubMed · Cited by 1
Memantine: from the original brand to generics
Titova, N. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2017117101136-143 · Cited by 1
Neuroinflammation in Alzheimer's Disease Continuum
Sag, A. T., & Yemişçi, M. (2020) · Neurological Sciences and Neurophysiology · doi:10.4103/nsn.nsn_190_20 · Cited by 1
Rational Therapeutics for Alzheimer's Disease and Other Dementias
Kowall, N. W. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch10
Le pire ennemi du sujet âgé : le fatalisme !
Péquignot, R. (2011) · Journal de Réadaptation Médicale Pratique et Formation en Médecine Physique et de Réadaptation · doi:10.1016/j.jrm.2010.08.002
La mémantine dans la maladie d'Alzheimer : Repousser le placement en CHSLD
Bouchard, R. W. (2009)
Managing Memory Impairment in Patients With Alzheimer’s Disease
Stark, A. C., & Budson, A. E. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.53
Development of nursing programme to assist medical treatment in early onset Alzheimer's disease
Ramström, I. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Hirni, D. I. (2015) · edoc (University of Basel) · doi:10.5451/unibas-006432938
Dementia- ja psyykenlääkkeiden käyttö dementian käytösoireiden hoidossa
Beshar, L. (2010) · Tampere University Institutional Repository (Tampere University)
Population-based studies on the natural history of Alzheimer's disease and vascular dementia
Imfeld, P. (2012) · edoc (University of Basel) · doi:10.5451/unibas-006021310
Amyloid beta 4-42 in Alzheimer’s disease: Target, Therapy, Mechanism
Antonios, G. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5611
Cholinesterasehemmer und Memantin in der symptomatischen Demenz-Therapie
Rodda, J. E., & Carter, J. (2013) · Praxis · doi:10.1024/1661-8157/a001209
2. Positioning for New Therapeutic Drugs of Dementia
Hishikawa, N., & Abe, K. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.1823
Molinuevo, J. L. (2011) · European Neurological Review · doi:10.17925/enr.2011.06.04.228
Gomes, S. M. (2017) · TSpace (University of Toronto)
Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease
Atri, A., & Stern, T. A. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150626-07
Kanaya, K., & Hanyu, H. (2017) · British Journal of Research · doi:10.21767/2394-3718.100013
López, O. L. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.07.002
Memantine (Generic and Namenda XR)
Budson, A. E., & Solomon, P. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28661-9.00017-2
Saha, S., Gerdtham, U., Toresson, H., Minthon, L., & Jarl, J. (2018) · RePEc: Research Papers in Economics
Базисная терапия болезни Альцгеймера: современные тенденции
журнала», Р. «. М., & Osadchy, A. (2019) · Український медичний часопис · doi:10.32471/umj.1680-3051.129.138365
Pharmacological Interventions in Older Adults
Patel, J. J., Smith, D. W., Heafner, J., Christopher, N. G., & Grossberg, G. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-10814-4_9
Nonmedical treatment of patients with dementia.
Howe, E. G. (2011) · Europe PMC (PubMed Central)
Levasseur, C. (2010) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2009.11.006
Current awareness in geriatric psychiatry
John Wiley & Sons, L. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2121
Budson, A. E., & Solomon, P. R. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-3597-8.00015-9
Deardorff, W. J., & Grossberg, G. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-74604-3_9
Larner, A. J. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6371-8_9
Current awareness in human psychopharmacology
(2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.978
Larner, A. J. (2011) · Springer eBooks · doi:10.1007/978-1-4471-2377-4_6
Larner, A. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139176095.004
Challenges of Combination Therapies in Alzheimer’s DiseasePreprint
Uddin, M. S. (2020) · doi:10.32545/encyclopedia202005.0004.v2
Schwarz, Š., & Frölich, L. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0912-0_15
Polypharmacology in Clinical Applications: Neurological Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_6
Chapter 24. Clinical Psychiatry in the Nursing Home
Lantz, M., Blissett, K.-A., & Streim, J. E. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375196.ds24
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.1 · Cited by 1
Follow-up Study of Treatment Adherence and Mortality in Alzheimer’s Disease
Sathiadevan, S., Varghese, M., Sivakumar, P. T., Loganathan, S., & Thennarasu, K. (2025) · Journal of Psychiatry Spectrum · doi:10.4103/jopsys.jopsys_17_25
Treatment of Alzheimer Disease: The Past, the Present, and the Future
Gauthier, S. G. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105601001
Kim, T., Hong, Y. J., Kim, M., Bae, Y., Lee, S. B., Kim, S. H., Lee, M. A., Ko, E., Park, J., & Yang, D. W. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01942-0
Alzate‐Correa, D., Stranan, J. P., Rincon‐Benavides, M. A., Mazo, N. A., Narváez-Pérez, L. F., Jaramillo-Garrido, S., Nguyen, T., Patel, R., Lawrence, W. R., Diaz‐Starokozheva, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.22.700900
Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer
Epelbaum, S. (2015) · theses.fr (ABES) · doi:10.70675/ea81e5c2z5032z4474z9f96z59f62125a629
Mobilisation de l'acide arachidonique et sensibilité au peptide ß-amyloïde
Thomas, M. H. (2015) · theses.fr (ABES) · doi:10.70675/904987d5zc8c8z4104z95dfz2f7e680d8be3
THERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB
Jońca, M., Majchrowicz, G., Kurys, N., Piekarska, W., Litke, S., & Gołacka, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5795
Svintozelskiy, P., Wahlert, A. J., Harrod, C., Kay, D. G., Grady, K. P., & Grossberg, G. T. (2026) · Sage Open Aging · doi:10.1177/30495334261485634
BindingDB (2022) · UC San Diego · doi:10.7270/q2222zkw
Sobów, T. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)
Metadata
- Authors
- Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2009-02-09
- Volume
- 80
- Issue
- 6
- Pages
- 600-607
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC2823571
- OpenAlex
- W2171545307
- Cited by
- 266
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 11 · 2019: 7 · 2018: 14 · 2017: 14 · 2016: 18 · 2015: 26 · 2014: 18 · 2013: 25 · 2012: 30
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institutes of Health (5p01ag003705-04)
- National Institute on Aging (AG 05-133, AG 20098, AG027224, P50AG005133, U01AG016976, AG 03705, R01AG020098, AG-16976, R56AG020098, R01AG027224)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, memantine, cholinesterase inhibitors, combination therapy, nursing home admission, time to death, NMDA receptor antagonists, long-term effects
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Drug Therapy, Combination, Female, Follow-Up Studies, Homes for the Aged, Humans, Male, Memantine, Mental Status Schedule, Neuropsychological Tests, Nursing Homes, Patient Admission, Survival Analysis, Excitatory Amino Acid Antagonists, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
